Michael Dell (Richard Drew, AP Images)
May 13, 2021 09:07 AM EDTUpdated 12:50 PM
Financing
Bioregnum

'Dude, you're get­ting a Del­l' — as a new deep-pock­et biotech in­vestor

What hap­pens when you mar­ry long­time in­sid­ers in the glob­al biotech VC game with the fam­i­ly fund of tech bil­lion­aire Michael Dell, a syn­thet­ic bi­ol­o­gy …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times